Literature DB >> 9254766

Ischaemic preconditioning does not protect hypertrophied myocardium against ischaemia.

J A Moolman1, S Genade, E Tromp, L H Opie, A Lochner.   

Abstract

OBJECTIVES: Because ischaemic preconditioning elicits a potent endogenous protective mechanism against the development of myocardial infarction, it is important to explore its utilisation in clinical situations. The aim of this study was to examine whether the myocardium of rats with genetic hypertension could be protected by ischaemic preconditioning.
METHODS: Male New Zealand genetically hypertensive rats (GH-Wistar-derived) and normotensive Wistar controls (WAG-Wistar-derived), aged 12 months, were used. Isolated perfused hearts were preconditioned by 3 periods of 5 minutes' global ischaemia, interspersed with 5 minutes' reperfusion, and subsequently subjected to 25 minutes' global ischaemia, followed by 30 minutes' reperfusion.
RESULTS: Heart and body mass were significantly higher in GH rats. Although the heart/body mass ratios of GH rats were higher than those of WAG rats, the difference was not significant. The reperfusion coronary flow pattern during the preconditioning protocol differed markedly between the 2 groups. Only normotensive WAG hearts demonstrated protective effects of preconditioning on post-ischaemic function and tissue creatine phosphate content, while the GH hearts could not be preconditioned.
CONCLUSIONS: An explanation for the failure of preconditioning in GH hearts is not yet available. The data caution against implementation of preconditioning in patients with angina pectoris and left ventricular hypertrophy.

Entities:  

Mesh:

Year:  1997        PMID: 9254766

Source DB:  PubMed          Journal:  S Afr Med J


  9 in total

Review 1.  Sarcolemmal dependence of cardiac protection and stress-resistance: roles in aged or diseased hearts.

Authors:  Louise E See Hoe; Lauren T May; John P Headrick; Jason N Peart
Journal:  Br J Pharmacol       Date:  2016-09-09       Impact factor: 8.739

2.  Hypertrophic preconditioning: short-term tricks for long-term gain.

Authors:  Arjun Deb; Yibin Wang
Journal:  Circulation       Date:  2015-03-27       Impact factor: 29.690

Review 3.  Opioid receptors and cardioprotection - 'opioidergic conditioning' of the heart.

Authors:  John P Headrick; Louise E See Hoe; Eugene F Du Toit; Jason N Peart
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

4.  Remote Limb Ischemic Conditioning and Motor Learning: Evaluation of Factors Influencing Response in Older Adults.

Authors:  Ellen N Sutter; Anna E Mattlage; Marghuretta D Bland; Kendra M Cherry-Allen; Elinor Harrison; Swati M Surkar; Jeffrey M Gidday; Ling Chen; Tamara Hershey; Jin-Moo Lee; Catherine E Lang
Journal:  Transl Stroke Res       Date:  2018-08-07       Impact factor: 6.829

Review 5.  Protection of the abnormal heart.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Dennis V Cokkinos
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

6.  Absence of ischemic preconditioning protection in diabetic sheep hearts: role of sarcolemmal KATP channel dysfunction.

Authors:  Héctor F del Valle; Elena C Lascano; Jorge A Negroni; Alberto J Crottogini
Journal:  Mol Cell Biochem       Date:  2003-07       Impact factor: 3.396

7.  Remote preconditioning in normal and hypertrophic rat hearts.

Authors:  Christos Voucharas; Antigoni Lazou; Filippos Triposkiadis; Nikolaos Tsilimingas
Journal:  J Cardiothorac Surg       Date:  2011-03-23       Impact factor: 1.637

Review 8.  Primary graft dysfunction after heart transplantation: a thorn amongst the roses.

Authors:  Sanjeet Singh Avtaar Singh; Jonathan R Dalzell; Colin Berry; Nawwar Al-Attar
Journal:  Heart Fail Rev       Date:  2019-09       Impact factor: 4.214

Review 9.  The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities.

Authors:  Kieran McCafferty; Suzanne Forbes; Christoph Thiemermann; Muhammad M Yaqoob
Journal:  Dis Model Mech       Date:  2014-12       Impact factor: 5.758

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.